Ihnken K, Speiser W, Müller-Berghaus G, Beyersdorf F, Schlepper M, Satter P
Abteilung für Thorax-, Herz- und Gefässchirurgie, Johann Wolfgang Goethe-Universität Frankfurt am Main.
Helv Chir Acta. 1992 Jan;58(4):503-8.
The fibrinolytic capacity of the blood mainly depends on the amount of tissue-plasminogen activator (t-PA) antigen and plasminogen activator inhibitor (PAI). In this study the fibrinolytic response to a venous occlusion test (VOT) was measured in 109 patients with angiographically documented coronary artery disease (CAD) and in 20 healthy volunteers at comparable age (controls). CAD-patients had higher plasma plasminogen activator inhibitor capacity before (24.4 +/- 11.0 vs. 15.4 +/- 5.2 arbitrary units [AU/ml]; p less than 0.0002) and after VOT (19.6 +/- 13.2 vs. 10.9 +/- 5.3 AU/ml; p less than 0.0001) compared with controls. Furthermore they showed significant lower plasma t-PA activity after VOT (3.0 +/- 6.8 vs. 6.6 +/- 10.6 AU/ml; p less than 0.0001). However there were no difference between both groups in plasma t-PA antigen levels after VOT (17.3 +/- 12.1 vs. 18.7 +/- 14.4 ng/ml). In 10% of patients the decrease in fibrinolytic activity resulted from a lower t-PA release ("lower" was defined as mean minus one standard deviation of the control group). 40% showed elevated plasma PAI capacity before VOT ("elevated" was defined as mean plus two standard deviations of the control group). Both caused significantly reduced post occlusion plasma t-PA activity and prolonged Euglobulin clot lysis time (p less than 0.003). A positive correlation was found between PAI capacity and serum triglyceride levels. Reduced fibrinolytic activity in 109 patients with coronary heart disease based either on a decrease in t-PA antigen release or a increased in PAI capacity in comparison with healthy controls. The mechanism of these findings is not yet well-known.(ABSTRACT TRUNCATED AT 250 WORDS)
血液的纤溶能力主要取决于组织型纤溶酶原激活物(t-PA)抗原和纤溶酶原激活物抑制剂(PAI)的量。在本研究中,对109例经血管造影证实患有冠状动脉疾病(CAD)的患者和20名年龄相仿的健康志愿者(对照组)进行了静脉闭塞试验(VOT)后的纤溶反应测量。与对照组相比,CAD患者在VOT前(24.4±11.0对15.4±5.2任意单位[AU/ml];p<0.0002)和VOT后(19.6±13.2对10.9±5.3 AU/ml;p<0.0001)的血浆纤溶酶原激活物抑制剂能力更高。此外,他们在VOT后的血浆t-PA活性显著降低(3.0±6.8对6.6±10.6 AU/ml;p<0.0001)。然而,两组在VOT后的血浆t-PA抗原水平上没有差异(17.3±12.1对18.7±14.4 ng/ml)。10%的患者纤溶活性降低是由于t-PA释放减少(“减少”定义为对照组平均值减去一个标准差)。40%的患者在VOT前血浆PAI能力升高(“升高”定义为对照组平均值加上两个标准差)。两者均导致闭塞后血浆t-PA活性显著降低,优球蛋白凝块溶解时间延长(p<0.003)。PAI能力与血清甘油三酯水平之间存在正相关。与健康对照组相比,109例冠心病患者的纤溶活性降低,其原因要么是t-PA抗原释放减少,要么是PAI能力增加。这些发现的机制尚不清楚。(摘要截取自250字)